Trial shows no clear benefit from cannabis for patients with MSBMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7424.1128 (Published 13 November 2003) Cite this as: BMJ 2003;327:1128
- Owen Dyer
The three year CAMS (cannabis in multiple sclerosis) trial, involving more than 600 patients in the United Kingdom, has yielded no definitive verdict on whether the drug can ease the symptoms of multiple sclerosis. The study, funded by the Medical Research Council, was published in last week's issue of the Lancet (2003;362: 1517-26).
Fifteen weeks' treatment with oral capsules containing either whole cannabis extract or tetrahydrocannabinol (THC), the drug's principal active ingredient, did not produce a significant improvement in spasticity as measured by the widely used Ashworth scale.
But in face to face interviews, patients assigned …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial